

## Guideline for the Prevention of Oral and Oropharyngeal Mucositis

### COG Supportive Care Endorsed Guidelines

Click [here](#) to see all the COG Supportive Care Endorsed Guidelines.

#### DISCLAIMER

**For Informational Purposes Only:** The information and contents offered in or in connection with the *Children's Oncology Group Supportive Care Endorsed Guidelines* (the "Guidelines") is provided only for informational purposes to children affected by cancer, their families and their health care providers. The Guidelines are not intended to substitute for medical advice, medical care, diagnosis or treatment obtained from doctors or other healthcare providers.

While the Children's Oncology Group tries to provide accurate and up-to-date information, the information in the Guidelines may be or may become out of date or incomplete. The information and guidelines may not conform to current standard of care, state-of-the art, or best practices for a particular disease, condition, or treatment. Some information in the Guidelines may be intended to be used by clinical researchers in special clinical settings or situations that may not apply to you, your child or your patient.

**Special Notice to cancer patients and their parents and legal guardians:** The Children's Oncology Group is a research organization and does not provide individualized medical care or treatment.

*The Guidelines are not intended to replace the independent clinical judgment, medical advice, screening, health counseling, or other intervention performed by your or your child's doctor or other healthcare provider. Please do not rely on this information exclusively and seek the care of a doctor or other medical professional if you have any questions regarding the Guidelines or a specific medical condition, disease, diagnosis or symptom.*

*Please contact "911" or your emergency services for any health emergency!*

**Special Notice to physicians and other healthcare providers:** This document is aimed specifically at members of the Children's Oncology Group or Member affiliates who have agreed to collaborate with the Children's Oncology Group in accordance with the relevant procedures and policies for study conduct and membership participation. Requirements and restrictions applicable to recipients of U.S. governmental funds or restrictions governing certain private donations may apply to the use and distribution of the Guidelines and the information contained herein.

The Guidelines are not intended to replace your independent clinical judgment, medical advice, or to exclude other legitimate criteria for screening, health counseling, or intervention for specific complications of childhood cancer treatment. The Guidelines provided are not intended as a sole source of guidance in the evaluation of childhood cancer patients. Nor are the Guidelines intended to exclude other reasonable alternative care. Specific patient care decisions are the prerogative of the patient, family and healthcare provider.

**Warranty or Liability Assumed by Children's Oncology Group and Related Parties:** While the Children's Oncology Group has tried to assure that the Guidelines are accurate and complete as of the date of publication, no warranty or representation, express or implied, is intended to be made in or with the Guidelines. No liability is assumed by the Children's Oncology Group or any affiliated party or member thereof for damage resulting from the use, review, or access of the Guidelines.

The “Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update” developed by the Pediatric Oncology Group of Ontario (POGO) was endorsed by the COG Supportive Care Guideline Committee in December 2021.

The source clinical practice guideline is published (Patel P, et al. Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update. Eur J Cancer 2021; 154: 92-101.) and is available at: <https://www.sciencedirect.com/science/article/pii/S095980492100321X>

The purpose of the source clinical practice guideline was to update the 2015 clinical practice guideline for mucositis prevention in pediatric cancer and HSCT patients. The recommendations of the source clinical practice guideline are presented below.

### Summary of Recommendations for the Prevention of Oral and Oropharyngeal Mucositis

RECOMMENDATIONS	Strength of Recommendation and Quality of Evidence*
What prophylactic interventions are effective at preventing or reducing the severity of oral and oropharyngeal mucositis in pediatric patients (0 to 18 years) receiving treatment for cancer or undergoing HSCT?	
<p>1. Use cryotherapy for older, cooperative pediatric patients receiving treatment for cancer or undergoing HSCT who will receive short infusions of melphalan or 5-fluorouracil.</p> <p><b>Remarks:</b> The panel valued the absence of documented adverse effects, low costs and consistent benefits associated with cryotherapy. The duration of melphalan and 5-fluorouracil administration in the included trials was 30 min or less where infusion duration was described. The panel did not believe that cryotherapy would be feasible for chemotherapy administrations longer than 1 h.</p>	<p>Strong recommendation High-quality evidence</p>

RECOMMENDATIONS	Strength of Recommendation and Quality of Evidence*
<p>2. Consider using cryotherapy for older, cooperative pediatric patients receiving treatment for cancer or undergoing HSCT who will receive short infusions of chemotherapy associated with mucositis other than melphalan or 5-fluorouracil.</p> <p><b>Remarks:</b> The panel hypothesized that the efficacy of cryotherapy is likely generalizable to chemotherapy other than melphalan and 5-fluorouracil. However, the indirectness of the data lowered the panel's certainty and resulted in a conditional recommendation. It is important to counsel families and patients that mucositis may develop even with diligent cryotherapy use, and the efficacy of cryotherapy may vary depending on the chemotherapy regimen administered.</p>	<p>Conditional recommendation Moderate-quality evidence</p>
<p>3. Do not administer palifermin routinely to pediatric patients with cancer receiving treatment for cancer or undergoing HSCT.</p> <p><b>Remarks:</b> While the panel acknowledged the significant reduction in severe mucositis associated with palifermin, the observed effect size was relatively modest. Based on its known short-term adverse effects, its potential for long-term negative effects on cancer outcomes, high costs and restricted availability, the panel made a strong recommendation against its routine use.</p>	<p>Strong recommendation High-quality evidence</p>
<p>4. Use intraoral photobiomodulation therapy in the red light spectrum (620–750 nm) for pediatric patients undergoing autologous or allogeneic HSCT and for pediatric patients who will receive radiotherapy for head and neck carcinoma.</p> <p><b>Remarks:</b> The panel valued the consistent benefits of photobiomodulation therapy and data regarding feasibility in pediatric patients. The ability to deliver photobiomodulation therapy requires specialized equipment, training and protective eyewear for the patient and those in attendance. The panel believed these requirements to be acceptable given the magnitude of benefit and the restricted patient populations included in the recommendation based on direct data. The ability to deliver photobiomodulation therapy to very young children requires assistance and support from family members and may not always be successful.</p>	<p>Strong recommendation High-quality evidence</p>

RECOMMENDATIONS	Strength of Recommendation and Quality of Evidence*
<p>5. Consider using intraoral photobiomodulation therapy in the red light spectrum (620–750 nm) for pediatric patients who will receive radiotherapy for head and neck cancers other than carcinoma.</p> <p><b>Remarks:</b> Although direct data were not available, the panel hypothesized that the efficacy of photobiomodulation therapy for head and neck carcinoma patients receiving radiotherapy is likely generalizable to pediatric patients who will receive radiotherapy for other head and neck cancers such as rhabdomyosarcoma. However, the indirectness of the data lowered the panel's certainty and resulted in a conditional recommendation.</p>	<p>Conditional recommendation Moderate-quality evidence</p>
<p>6. Do not administer GCSFs to pediatric patients receiving treatment for cancer or undergoing HSCT for the purpose of mucositis prevention.</p> <p><b>Remarks:</b> While the panel recognized that patients receive GCSFs for other indications including shortening the duration of neutropenia, the absence of benefit, adverse effects and costs led the panel to make a strong recommendation against its use for the purpose of mucositis prevention.</p>	<p>Strong recommendation High-quality evidence</p>

\*see Appendix 1

HSCT: hematopoietic stem cell transplant; GCSFs: granulocyte colony-stimulating factors

## Appendix 1: GRADE

### Strength of Recommendations:

<b>Strong Recommendation</b>	When using GRADE, panels make strong recommendations when they are confident that the desirable effects of adherence to a recommendation outweigh the undesirable effects.
<b>Weak or Conditional Recommendation</b>	Weak or conditional recommendations indicate that the desirable effects of adherence to a recommendation probably outweigh the undesirable effects, but the panel is less confident.

### Strength of Recommendation Determinants:

Factor	Comment
Balance between desirable and undesirable effects	The larger the difference between the desirable and undesirable effects, the higher the likelihood that a strong recommendation is warranted. The narrower the gradient, the higher the likelihood that a weak recommendation is warranted
Certainty in evidence	The higher the quality of evidence, the higher the likelihood that a strong recommendation is warranted
Values and preferences	The more values and preferences vary, or the greater the uncertainty in values and preferences, the higher the likelihood that a weak recommendation is warranted
Costs (resource allocation)	The higher the costs of an intervention—that is, the greater the resources consumed—the lower the likelihood that a strong recommendation is warranted

### Certainty in Evidence or Quality of Evidence

<b>High Certainty/Quality</b>	Further research is very unlikely to change our confidence in the estimate of effect
<b>Moderate Certainty/Quality</b>	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
<b>Low Certainty/Quality</b>	Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
<b>Very Low Certainty/Quality</b>	Any estimate of effect is very uncertain

Guyatt, G.H., et al., *GRADE: an emerging consensus on rating quality of evidence and strength of recommendations*. BMJ, 2008; 336: 924-926.

Guyatt, G.H., et al., *GRADE: going from evidence to recommendations*. BMJ, 2008; 336: 1049-1051.